Sensei Biotherapeutics (NASDAQ:SNSE) Upgraded at HC Wainwright

HC Wainwright upgraded shares of Sensei Biotherapeutics (NASDAQ:SNSE) to a buy rating in a research note issued to investors on Monday morning, Marketbeat.com reports. The firm currently has $5.00 price objective on the stock. HC Wainwright also issued estimates for Sensei Biotherapeutics’ Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.36) EPS, FY2025 earnings at ($1.27) EPS, FY2026 earnings at ($1.29) EPS and FY2027 earnings at ($1.19) EPS.

A number of other brokerages have also weighed in on SNSE. Oppenheimer boosted their price target on Sensei Biotherapeutics from $3.50 to $4.00 and gave the stock an “outperform” rating in a research note on Friday, March 28th. Stephens raised shares of Sensei Biotherapeutics to a “strong-buy” rating in a research report on Thursday, May 1st.

Sensei Biotherapeutics Stock Performance

Shares of NASDAQ SNSE opened at $0.35 on Monday. Sensei Biotherapeutics has a 52-week low of $0.25 and a 52-week high of $0.87. The firm has a market capitalization of $8.88 million, a price-to-earnings ratio of -0.30 and a beta of 0.19. The stock has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.44.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.06). Analysts forecast that Sensei Biotherapeutics will post -1.17 earnings per share for the current year.

Institutional Trading of Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. XTX Topco Ltd boosted its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 351.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 62,903 shares of the company’s stock after buying an additional 48,977 shares during the period. XTX Topco Ltd owned approximately 0.25% of Sensei Biotherapeutics worth $31,000 at the end of the most recent quarter. Institutional investors and hedge funds own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.